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Background: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) results from incomplete resolution of
a pulmonary embolus, leading to pulmonary hypertension and progressive right heart failure and death. We
aimed to describe the demographics, treatment patterns, health resource utilization and related costs of
patients with CTEPH.
Methods: In specialized PH centres across six European countries, medical charts of CTEPH patients on PH
medication were retrospectively extracted (chart review between 2006 and 2009). Resource utilization was
valued using country-specific unit costs. Descriptive statistical analyses were performed.
Results: Twenty-one hospitals documented 119 consecutive CTEPH patients over an average of 25.4 months.
Patients were inoperable (83.9%) or persistent after surgery (16.0%) with mean age 67.5 ± 12.3 years, 61% were
female. The average 6-minute walking distance was 298 ± 120 meters, and NYHA class II/III/IV was 27/59/14%. At
baseline, 59.7% patients received endothelin receptor antagonist, 34.4% phosphodiesterase-5 inhibitors, and
5.8% prostacyclin. Adding a second PH medication was the most common regimen change. CTEPH patients
experienced 1.8 ± 2.2 hospitalizations per year accounting for 14.8 ± 26.1 days in hospital. Patients paid on
average 2.8 office visits per year to their general practitioner and 1.3 visits to a specialist. Unadjusted annual
mortality rate was 6.0%. Annual cost of PH specific medication was the predominant economic factor averaging €
36,768 per year. Costs for hospitalizations (€ 4,496) and concomitant medications (€ 2,510) were substantially lower.
Other health care resource items only accounted for marginal additional costs.
Conclusion: CTEPH patients are characterised by substantial morbidity and mortality. Health care utilisation,
predominantly due to off-label use of PH drugs, is significant.
Keywords: Retrospective, Chart review, Pulmonary hypertension, Treatment, Cost* Correspondence: bernd.schweikert@optum.com
1OptumInsight, Konrad-Zuse-Platz 11, D- 81829 Munich, Germany
Full list of author information is available at the end of the article
© 2014 Schweikert et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited.
Schweikert et al. BMC Health Services Research 2014, 14:246 Page 2 of 7
http://www.biomedcentral.com/1472-6963/14/246Background
Pulmonary hypertension (PH) is a debilitating disease of
the pulmonary artery branches characterized by increased
pulmonary arterial pressure and pulmonary vascular re-
sistance [1,2]. The condition is often associated with pro-
gressive right ventricular failure and a poor prognosis. An
important and cause of PH is chronic thromboembolic
PH (CTEPH), which is the result of pulmonary vascular
obstruction characterized by recurrent, unresolved pul-
monary emboli and/or progressive pulmonary vascular
thrombosis and scarring [3].
Prospective studies indicate that between 0.6% and 4.6%
of acute pulmonary embolic survivors develop symptom-
atic CTEPH [4,5]. Furthermore, approximately 30% to
50% of CTEPH patients have been reported not having a
history of acute venous thromboembolism [6,7].
Due to the rarity and complexity of the condition, pa-
tients with CTEPH according to international and national
PH guidelines should be treated in expert centres only [1].
The treatment of choice for CTEPH is surgical pulmonary
endarterectomy (PEA), which provides a potential cure of
the disease, in particular if performed at expert centres with
this surgical capability [8]. However, a substantial portion of
patients may be considered ‘inoperable’ due to distal loca-
tion of pulmonary thromboembolic or severe comorbidity
and have a poor prognosis if untreated [9,10]. In addition,
roughly 10% of patients who undergo PEA maintain a pul-
monary hypertensive state since they obtain limited relief
from surgery or experience recurrence [9]. Such inoperable
or residual/recurrent patients are frequently treated with
PH drugs (off-label) due to the lack of other treatment
alternatives [11]. To date, positive randomized control
trial evidence for medication use in CTEPH has only re-
cently been demonstrated in the CHEST-1 study with
riociguat [12]. Only very recently a drug has been ap-
proved for the treatment of CTEPH in Europe and the
US. Additionally, there is a lack of data on costs and re-
source utilization associated with CTEPH in patients in
the real-world setting.
Against this background, we aimed to describe the
demographics, drug treatment patterns, outcomes and
costs of patients with CTEPH treated under everyday
practice conditions in six European countries.
Methods
Design and organisation
This present study was a retrospective chart review in
21 specialist centres in six countries: France (3 centres),
Spain (4), Italy (4), UK (3), Sweden (1), and Germany
(3). Data from consecutive patients were collected at
each site for a maximum of up to 39 months after the
initiation visit within the observation period between
July 2006 and September 2009. The ethics review
boards of each centre approved data collection, and dataprotection rules were closely observed (see Additional file 1
for a complete list of the involved ethic commissions and
review boards). Patients were eligible for inclusion, if they
were at least 18 years old, had a confirmed diagnosis of
CTEPH (Group 4 according to Dana Point 2008 criteria),
were in NYHA class II to IV, treated with monotherapy or
combination therapy with endothelin receptor antagonists
(ERA), prostacyclin analogues (PA) or phosphodiesterase-5
(PDE-5) inhibitors. The only exclusion criterion was HIV.
Written informed consent was obtained from the pa-
tients according to local regulations and in line with the
recommendation of the responsible ethic committees and
review boards.
Patient variables
Information was collected on demographics (age, gender,
employment status etc.), diagnostic information (type of
CTEPH with differentiation between inoperable or oper-
ated patients with persisting and recurrent PH after PEA;
time since first diagnosis), clinical data (New York Heart
Association [NYHA] class, 6-minute walk distance, Borg
dyspnoea index), hemodynamic and lung function (pul-
monary artery pressure, pulmonary capillary wedge pres-
sure, pulmonary vascular resistance, right atrial pressure,
cardiac index, respiratory capacity), comorbidities and risk
factors (smoking, alcohol consumption etc.). Detailed infor-
mation was collected on treatments focussing on PH drugs,
i.e. the endothelin receptor antagonists (ERA) ambrisentan,
bosentan, and sitaxentan, the PDE-5 inhibitors sildenafil
and tadalafil, or prostacyclines. Dosages were recorded. Fur-
ther, co-medication with calcium channel blockers, di-
uretics and digoxin were recorded at the class level. With
respect to outcomes, the following events were recorded:
lung or heart lung transplantation, atrial septostomy, PEA,
hospitalisation, ambulatory/outpatient centre visits, exami-
nations and procedures, and other health care services.
Data collection
Data were extracted from patient files by staff members of
the individual sites according to guidelines provided for
this procedure. Standardized case report forms were used.
Data were entered into the database at a central site, and
checked for plausibility and completeness. In case of miss-
ing data or queries, sites were contacted to resolve the is-
sues. No on-site monitoring was performed.Statistical analysis
Due to the nature of the study and the small patient popu-
lation, all statistical analyses were exploratory and used in a
descriptive manner. Incidence rates, time to first event and
standard deviations were provided for discrete variables.
Means per year of follow-up and standard deviations were
presented for continuous variables. For survival analysis,
Table 1 Baseline characteristics
Baseline variable Sample size (N)* Value
Age, years (mean ± SD) 119 67.5 ± 12.3
Gender, female, % 119 60.5
BMI, kg/m2 (mean ± SD) 112 26.8 ± 5.4
Comorbidities, number 119 3.4 ± 1.9
NYHA class, (mean ± SD) 119 2.9 ± 0.6
class, II, III, IV (%) 119 27/ 59/ 14
6-min walk distance, (mean ± SD) 92 298 ± 120
History of PH, months (mean ± SD) 116 16.0 ± 47.3
Inoperable CTEPH, % 118 83.9
*Sample size may vary due to missing values in the patient records.
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Results
Disposition and characteristics
Of 119 CTEPH patients, 49 (41.2%) were documented in
France, 34 (28.6%) in Germany, 17 (14.3%) in the UK, 9
(7.6%) in Italy, 7 (5.9%) in Spain, and 3 (2.5%) in Sweden.
Mean observation time was 25.4 ± 25.6 months, and the
mean number of recorded visits 7.1 ± 3.3. Baseline charac-
teristics are summarized in Table 1. Patients were on aver-
age 67.5 ± 12.3 years old, women accounted for 60.5%.
Time since PH diagnosis was 16.0 ± 47.3 months.
Comorbidities were prevalent (mean number per patient
3.4 ± 1.9), with the most frequent ones including arterial
hypertension (41 patients, 34.2%), pulmonary embolism
with or without acute cor pulmonale (30.0%), other pul-
monary heart disease (17.5%), phlebitis and thrombophle-
bitis (14.2%), and heart failure or chronic obstructive
pulmonary disease (10% each). Patients were defined as in-
operable in 99 cases (83.9%) and as having persisting or
recurrent PH after PEA in 19 cases (16.0%; 1 patient with
missing information).Table 2 Clinical outcomes and hemodynamics, baseline and c
Parameter Bas
N*
6 MWD, meters 92
Pulmonary atrial pressure (PAP),mmHg 107
Pulmonary capillary wedge pressure, mm Hg 98
Right atrial pressure (RAP), mmHg 96
Pulmonary vascular resistance (PVR), dyn × sec × cm−5 94
Cardiac index, l/min/m2 98
Borg dyspnoea index 81
FEV1, litres 86
FEV1/vital capacity 87
*Sample size may vary due to missing values in the patient records.
FEV1, Forced Expiratory Volume in 1 second; 6-MWD, walking distance in 6 minutesMean 6-minute walking distance was low (298 ± 120
meters). Most patients were in NYHA classes II (26.8%) or
III (58.8%), and fewer in IV (14.3%). Hemodynamic are
displayed in Table 2. Mean pulmonary arterial pressure
was 46 ± 11 mmHg, mean pulmonary vascular resistance
797 ± 416 dyn × sec × cm−5.
Medication
PH drugs were used off-label in CTEPH (Figure 1). At the
time of the data collection, monotherapy prevailed, mostly
with bosentan (68 patients, 57.6%), sildenafil (39 patients,
33.1%), or epoprostenol (3.4%). All other drugs were re-
ported in less than 2% of patients. Combination therapy
was reported in 1 patient only (ERA plus PDE-5 inhibitor).
As concomitant medications, mainly anticoagulants (62.5%)
and diuretics were noted (59.2%). Oxygen was used in every
fourth patient (25.8%, Figure 2).
Medication changes over time are shown in Figure 3.
Discontinuation of the first therapy was infrequent (6
cases on bosentan and 6 cases on sildenafil, 5.0% each).
Switch from bosentan to another ERA occurred in 16
cases (13.3%) and to a PDE-5 inhibitor in 5 cases (4.2%),
while switch from sildenafil to ERA occurred only in 1 pa-
tient (0.8%), and to other PDE-5 inhibitors in 5 patients
(4.2%). One patient on epoprostenol (0.8%) switched to
another prostacyclin, and another patient to an ERA.
Adding a second PH medication was the most common
regimen change. For bosentan, in 29 patients (24.2%) a
PDE-5 inhibitor was added, in 2 cases (1.7%) another
ERA, and in 1 case (0.8%) a prostacyclin. For sildenafil, in
11 cases (9.2%) an ERA was added and in 1 case (0.8%) a
prostacyclin. For prostacyclin, in 1 case each (0.8% each)
an ERA or a PDE-5 inhibitor was added.
Clinical course
Most patients were relatively stable during follow-up in
terms of hemodynamics (Table 2) and events. Six-minute
walking distance increased by 30.3 meters. At the lasthange during follow-up
eline Follow-up
Mean ± SD N* Δ during observation (Mean ± SD)
298 ± 120 90 30 ± 90
45.5 ± 0.6 51 −2.5 ± 13.4
9.5 ± 4.6 43 −1.0 ± 5.9
8.1 ± 5.8 53 −0.43 ± 6.7
797 ± 416 37 −111 ± 360
2.2 ± 0.5 49 1.11 ± 3.3
4.7 ± 2.2 78 −0.5 ± 2.7
2.0 ± 0.7 71 −0.1 ± 0.3
71.5 ± 12.3 72 −3.1 ± 10.4
.
Figure 1 PH-specific medication at inclusion (% of patients).
Medication for PH at time of inclusion (% of patients).
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improved with respect to NYHA class, 69% (58.0%) had
remained stable, and 10 (8.4%) had deteriorated.
Surgical interventions comprised 9 PEA (8.3%) and 1
atrial septostomy (0.8%). A total of 15 patients (12.6%)
died during observation, with an unadjusted annual mor-
tality rate of 6.0%. Time to death in inoperable CTEPH
versus residual PH is shown in Figure 4, indicating a sub-
stantially higher mortality and significant unmet need for
CTEPH patients who are not eligible for PEA surgery.
Resource utilization and costs
Patients had on average 2.8 ± 4.2 office visits with their
general practitioner and 1.3 ± 1.4 visits to a specialist per
year (Table 3). Hospitalisations were frequent (1.8 ± 2.2
per patient and year), as were examinations or diagnostic
tests (8.4 ± 5.9).Figure 2 Co-medication and accompanying treatment (% of patients)Annual costs of PH medication was the predominant
cost factor (36,768 € ± 22,630), followed by costs for hos-
pitalisations (4,496 € ±7,923) and concomitant medica-
tions (2,510 € ±2,503, Figure 5). Costs for ambulatory
visits to GPs and specialists were negligible (<100 € each
per patient and year).
Other health care resource items only accounted for
marginal additional costs in both groups. Medical aids
such as walking aids, inhalation devices or physiotherapy,
were documented for one out of four patients.
Discussion
The present analysis provides insight about the situation
and resource utilisation of CTEPH patients in a sample
of European specialist centres during the years 2006 to
2009. In line with a report of a large-scale European
registry performed in 2007 to 2009 [6], our study shows
that off-label treatment with PH drugs is common prac-
tice in patients with inoperable or residual CTEPH.
Most patients were severely impaired as indicated by
their NYHA class, exercise capacity (6-minute walk dis-
tance), hemodynamics and comorbidities. Compared to
patients in the international prospective CTEPH registry
performed in 2007–2009, patients in our cohort were
somewhat older (68 versus 63 years), comprised more
women (61% versus 50%), had a lower 6-minute walking
distance (298 versus 329 meters), and a lower portion of
inoperable patients (83% versus 36%) [6].
Drug treatment accounted for the largest share of direct
costs for patients in the present chart review, while costs
for hospitalisations and concomitant treatment were much
lower, and costs for GP or specialists visits were negligible.
To our knowledge, there are only two other studies that
also reported the cost dimension of patients with CTEPH.
First, Kirson et al. reported a series of 289 privately insured
CTEPH patients in the US (mean age 52.2 years, 57.1%
women), for whom mean direct costs per month (year. Co-medication and accompanying treatment at time of inclusion.
Figure 3 Changes in treatment during follow-up (percent of patients). Percentage of patients on medication for the three most common
medications.
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compared to USD 511 [6132/year] for controls, (p <
0.0001), and USD 2,023 [USD 24,276/year] for patients
with pulmonary arterial hypertension (PAH) [13,14]. In
that sample, inpatient services accounted for 54%, out-
patient and other services for 33% and prescription drugs
for 11% of total direct healthcare costs per patient-month
in CTEPH patients [13]. Second, Said et al. estimated direct
medical costs and resource use for commercially in-
sured CTEPH patients during 2004–2009 within the
US-American MarketScan database using a retrospective
cohort design [15]. Compared to matched controls with-
out CTEPH or PAH, CTEPH patients had significantlyFigure 4 Survival, by PEA status. Kaplan-Meier curve of survival by status
CTEPH after PEA.higher monthly costs and resource use (total costs 6198
USD [$74,376/year] versus 1,579 USD [$18,948/year], out-
patient visits 1.2 versus 0.8, inpatient visits 2 versus 0.2,
prescriptions 4.2 versus 2.8; all p-values <0.05) [15].
Other groups have published cost-utility [16], cost-
effectiveness [17] or cost-minimisation analyses [18]
for PAH (but not CTEPH) based on populations in the
USA or Canada. For example, in a retrospective study
similar to ours (claims database analysis) with 706 PAH
patients in a large, geographically diverse US managed-
care organization, PAH drugs were the main cost driver
compared to PAH-related inpatient stays and emergency
department visits, with average monthly costs of 5,332of pulmonary endartherectomy: blue = inoperable, red = persisting
Table 3 Resource utilization
Resource N* Mean ± SD Median
Hospitalizations per PY 118 1.8 ± 2.2 1.0
Hospitalization days per PY 74 14.8 ± 26.1 7.8
Time to first hospitalization (d) 74 146 ± 209 71.5
Examinations/tests per PY 118 8.4 ± 5.9 7.8
Visits to the GP per PY 64 2.8 ± 4.2 0.7
Visits to specialists per PY 77 1.3 ± 1.4 0.9
Medical aids per PY 48 0.6 ± 2.1 0
*Sample size may vary due to missing values in the patient records.
D = day; GP = general practitioner; PY = patient year.
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respectively (p = 0.003) [19].
Limitations of the study
A number of methodological considerations and limitations
have to be taken into account when interpreting the
current data. Data have to be interpreted carefully taking
the principle limitations of a retrospective analysis into ac-
count, in particular: missing data, varying follow-up periods
for patients, variation in reporting and documentation
across sites and countries [20]. The comprehensive meas-
urement of health care utilization is known to be challen-
ging in studies which cannot rely on administrative data
(preferably payer data).
It was anticipated that the availability of these types of
utilization data depended on the country or even site-
specific degree of service integration as well as the infor-
mational exchange across health care service providers
(e.g. PH treatment centre and general practitioner).
Missing data in particular with respect to medical aids
were frequent. Therefore a total cost estimate could not
be provided, as it would have been based on the smallFigure 5 Yearly costs related treatment of CTEPH. Mean
annualized cost of health care related to CTEPH treatment. Main
treatment categories. Whiskers represent standard deviation.sample of patients when restricting aggregation to the
patients with complete information. Relying on available
information would have led to significant underestima-
tion of total costs. However, the direct costs for medica-
tions outnumber other cost components by far.
Furthermore, the study focused on inoperable CTEPH
patients treated with PH medication excluding patients
that were not on PH medication. Although no PH medica-
tion had been approved for CTEPH at the time of the
study, ERA, PA and PDE-5 inhibitors have already been
widely used as suggested by guidelines as the treatment of
choice. A further obvious limitation is the sample size of
this study and the selection process using a centre-based
approach. However, given the severity and rareness of the
disease and the still limited number of observational stud-
ies investigating the condition, this study adds to the
knowledge base by reporting clinical and economic out-
comes from a real world sample.
Conclusions
While CTEPH is the only form of PH that currently can
be potentially cured, a substantial portion of patients are
either inoperable or decline operation, or experience re-
current PH after the PEA. Physicians face a dilemma when
treating such patients, as no drug has consistently demon-
strated efficacy and received regulatory approval for the
treatment of CTEPH. In the present study, CTEPH pa-
tients who were inoperable had a significantly worse prog-
nosis compared to patients post-PEA. CTEPH patients
had high resource utilization and costs, with off-label PH
medications accounting for the highest costs. More re-
search is required in the real-world setting to understand
the cost implications of using off-label medications with-
out demonstrated efficacy in randomized controlled trials.
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